The Application of an Innovative Reactive Agility Testing System for Assessment in Older Adults With Dynapenia

January 21, 2026 updated by: Fan-Chen Liu, Kaohsiung Medical University

Before the experiment, the researchers explain the purpose and procedures to the participants. After signing the informed consent form and completing basic personal information, participants perform a 5-minute warm-up. They then practice the test procedure 1-3 times to become familiar with the visual stimuli, followed by a 3-minute rest before the formal experiment.

Body composition and physical performance are assessed using handgrip strength, the five-time sit-to-stand test, and the skeletal muscle mass index.

Fall risk is evaluated using a localized fall risk awareness questionnaire.

Agility is tested using a reaction-based running task. Participants stand in a 1 m × 1 m preparation area, and one of two sensor lights placed 3 meters away lights up randomly. Participants run forward, pass through a photo gate, and touch the light to turn it off. Decision time, movement time, and total time are recorded over 10 trials.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Before the experiment begins, the researchers will first explain the experimental procedures and purpose to the participants. Participants will then complete an informed consent form and provide their basic personal information. After that, participants will perform a 5-minute warm-up exercise.

To familiarize participants with the visual stimuli, they will practice the test procedure one to three times. After the practice session, participants will rest for 3 minutes before the formal experiment begins.

  • (1) Body Composition and Physical Performance Data

    • **Handgrip Strength:** Measured using a handgrip dynamometer. Three trials are performed, and the maximum value is recorded as the handgrip strength.
    • **Five-Time Sit-to-Stand Test:** The participant sits on a standard testing chair with the hips and knees flexed at 90 degrees. Without using the hands for assistance, the participant performs five sit-to-stand movements as quickly as possible. The completion time is recorded.
    • **Skeletal Muscle Mass Index (SMI):** The participant stands barefoot on the measurement device and holds the hand electrodes to obtain appendicular muscle mass. The appendicular muscle mass is then divided by height squared to calculate the skeletal muscle mass index.
  • (2) Fall Risk

Fall risk is assessed using a localized Fall Risk Awareness Scale. A higher score indicates a greater risk of falling and a higher level of fear of falling.

### (3) Agility Test

The participant stands in the preparation area located at the center of the testing field, which measures 1 m × 1 m. One sensor light is placed on each side, each positioned 3 meters away from the preparation area.

After the system is activated, one of the lights will illuminate randomly between 1 and 5 seconds. Once the light turns on, the participant moves forward quickly, passes through a photo gate next to the preparation area, and continues forward until touching the sensor light to turn it off.

The system records:

  • **Decision time:** the time from when the light turns on to when the participant passes through the photo gate.
  • **Movement time:** the time from passing through the photo gate to touching and turning off the sensor light.

After a total of 10 trials (combined left and right sides), the test ends. Finally, the system calculates the **total time**, which is the sum of the decision time and movement time.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
104

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Taiwan
      • Kaohsiung City, Taiwan, 807
        • Kaohsiung Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Community-dwelling older adults aged 65 years and above Able to communicate with the researchers through spoken or written language Able to cooperate with all required assessments

Description

Inclusion Criteria:

  • Community-dwelling older adults aged 65 years and above
  • Able to communicate with the researchers through spoken or written language
  • Able to cooperate with all required assessments

Exclusion Criteria:

  • Individuals with cognitive impairment
  • Individuals who experience chest pain during recent exercise
  • Individuals with angina or joint pain
  • Individuals with congestive heart failure
  • Individuals who have been advised by a physician not to exercise
  • Patients with cancer currently receiving chemotherapy or radiotherapy
  • Individuals with neuromuscular disorders or musculoskeletal injuries involving the ankle, knee, or hip joints

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Healthy Elderly
Normal muscle mass Normal muscle strength Normal physical performance
Diagnostic test: Reactive Agility Testing System

The participant stands in the preparation area located at the center of the testing field, which measures 1 m × 1 m. One sensor light is placed on each side, with each light positioned 3 meters away from the preparation area.

After the system is activated, one of the lights will illuminate randomly between 1 and 5 seconds. Once the light turns on, the participant moves forward quickly, passes through a photo gate next to the preparation area, and continues forward until touching the sensor light to turn it off.

The system records the time from when the light turns on to when the participant passes through the photo gate, which is defined as the decision time. The time from passing through the photo gate to touching and turning off the sensor light is defined as the movement time.

After completing five trials on each side, the test ends. Finally, the system calculates the total time, which is the sum of the decision time and movement time.
Pre sarcopenia
Low muscle mass Normal muscle strength Normal physical performance
Diagnostic test: Reactive Agility Testing System

The participant stands in the preparation area located at the center of the testing field, which measures 1 m × 1 m. One sensor light is placed on each side, with each light positioned 3 meters away from the preparation area.

After the system is activated, one of the lights will illuminate randomly between 1 and 5 seconds. Once the light turns on, the participant moves forward quickly, passes through a photo gate next to the preparation area, and continues forward until touching the sensor light to turn it off.

The system records the time from when the light turns on to when the participant passes through the photo gate, which is defined as the decision time. The time from passing through the photo gate to touching and turning off the sensor light is defined as the movement time.

After completing five trials on each side, the test ends. Finally, the system calculates the total time, which is the sum of the decision time and movement time.
Sarcopenia
Low muscle mass Low muscle strength or low physical performance
Diagnostic test: Reactive Agility Testing System

The participant stands in the preparation area located at the center of the testing field, which measures 1 m × 1 m. One sensor light is placed on each side, with each light positioned 3 meters away from the preparation area.

After the system is activated, one of the lights will illuminate randomly between 1 and 5 seconds. Once the light turns on, the participant moves forward quickly, passes through a photo gate next to the preparation area, and continues forward until touching the sensor light to turn it off.

The system records the time from when the light turns on to when the participant passes through the photo gate, which is defined as the decision time. The time from passing through the photo gate to touching and turning off the sensor light is defined as the movement time.

After completing five trials on each side, the test ends. Finally, the system calculates the total time, which is the sum of the decision time and movement time.
Dynapenia
Normal muscle mass Low muscle strength or low physical performance
Diagnostic test: Reactive Agility Testing System

The participant stands in the preparation area located at the center of the testing field, which measures 1 m × 1 m. One sensor light is placed on each side, with each light positioned 3 meters away from the preparation area.

After the system is activated, one of the lights will illuminate randomly between 1 and 5 seconds. Once the light turns on, the participant moves forward quickly, passes through a photo gate next to the preparation area, and continues forward until touching the sensor light to turn it off.

The system records the time from when the light turns on to when the participant passes through the photo gate, which is defined as the decision time. The time from passing through the photo gate to touching and turning off the sensor light is defined as the movement time.

After completing five trials on each side, the test ends. Finally, the system calculates the total time, which is the sum of the decision time and movement time.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Decision time
Time Frame: From participant enrollment to the end of testing
The system records the time from when the light turns on to when the participant passes through the photo gate, which is defined
From participant enrollment to the end of testing
movement time
Time Frame: From participant enrollment to the end of testing
The time from passing through the photo gate to touching and turning off the sensor light
From participant enrollment to the end of testing

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Handgrip Strength
Time Frame: From participant enrollment to the end of testing
Measured using a handgrip dynamometer. Three trials are performed, and the highest value is recorded as handgrip strength.
From participant enrollment to the end of testing
Five-Time Sit-to-Stand Test
Time Frame: From participant enrollment to the end of testing
The participant sits on a standard testing chair with the hips and knees flexed at 90 degrees. Without using the hands for assistance, the participant performs five sit-to-stand movements as quickly as possible. The completion time is recorded.
From participant enrollment to the end of testing
Skeletal Muscle Mass Index (SMI)
Time Frame: From participant enrollment to the end of testing
The participant stands barefoot on the measurement device and holds the hand electrodes to obtain appendicular muscle mass. The appendicular muscle mass is then divided by height squared to calculate the skeletal muscle mass index.
From participant enrollment to the end of testing

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Kaohsiung Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 24, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 24, 2025

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 24, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 14, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 21, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 29, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 29, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 21, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • KMUHIRB-E(I)-20250028 (Other Identifier: Kaohsiung Medical University Chung-Ho Hospital Institutional Review Board)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Sharing Time Frame

De-identified individual participant data (IPD) and supporting information will be available starting 2 years after the publication of the primary study results and will remain accessible for 5 years.

IPD Sharing Access Criteria

The related supporting documents will only be made available to qualified researchers affiliated with academic institutions, medical organizations, or public health agencies, Applicants must submit a detailed research proposal and ethical approval documents, and access will be granted only upon approval.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dynapenia

Clinical Trials on Reactive Agility Testing System

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings